Clinical Trial Update: Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML [Phase 1]

View source ↗

Summary

Phase I study evaluating AZD2171 in relapsed/refractory acute myeloid leukemia and in elderly patients with de novo or secondary AML has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Leukaemia, Myelocytic | Phase 1 | Status: COMPLETED